Trials / Completed
CompletedNCT05938920
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- InSilico Medicine Hong Kong Limited · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INS018_055 | Pharmaceutical formulation: Capsules Mode of Administration: Oral |
| DRUG | Placebo | Pharmaceutical formulation: Capsules Mode of Administration: Oral |
Timeline
- Start date
- 2023-06-19
- Primary completion
- 2024-08-08
- Completion
- 2024-08-08
- First posted
- 2023-07-11
- Last updated
- 2025-12-11
- Results posted
- 2025-12-02
Locations
22 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05938920. Inclusion in this directory is not an endorsement.